Literature DB >> 15496975

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).

R L Levine1, M Wadleigh, D W Sternberg, I Wlodarska, I Galinsky, R M Stone, D J DeAngelo, D Gary Gilliland, J Cools.   

Abstract

We report the cloning of a novel PDGFRB fusion gene partner in a patient with a chronic myeloproliferative disorder characterized by t(5;14)(q33;q32), who responded to treatment with imatinib mesylate. Fluorescence in situ hybridization demonstrated that PDGFRB was involved in the translocation. Long distance inversion PCR identified KIAA1509 as the PDGFRB fusion partner. KIAA1509 is an uncharacterized gene with a predicted coiled-coil oligomerization domain with homology to the HOOK family of proteins. The predicted KIAA1509-PDGFRbeta fusion protein contains the KIAA1509 coiled-coil domain fused to the cytoplasmic domain of PDGFRbeta that includes the tyrosine kinase domain. Imatinib therapy resulted in rapid normalization of the patient's blood counts, and subsequent bone marrow biopsies and karyotypic analysis were consistent with sustained complete remission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15496975     DOI: 10.1038/sj.leu.2403548

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  The Dishevelled-associating protein Daple controls the non-canonical Wnt/Rac pathway and cell motility.

Authors:  Maki Ishida-Takagishi; Atsushi Enomoto; Naoya Asai; Kaori Ushida; Takashi Watanabe; Takahiko Hashimoto; Takuya Kato; Liang Weng; Shinji Matsumoto; Masato Asai; Yoshiki Murakumo; Kozo Kaibuchi; Akira Kikuchi; Masahide Takahashi
Journal:  Nat Commun       Date:  2012-05-29       Impact factor: 14.919

2.  Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Authors:  Chan Y Cheah; Kate Burbury; Jane F Apperley; Francoise Huguet; Vincenzo Pitini; Martine Gardembas; David M Ross; Donna Forrest; Philippe Genet; Philippe Rousselot; Nigel Patton; Graeme Smith; Cynthia E Dunbar; Sawa Ito; Ricardo C T Aguiar; Olatoyosi Odenike; Alla Gimelfarb; Nicholas C P Cross; John F Seymour
Journal:  Blood       Date:  2014-03-31       Impact factor: 22.113

Review 3.  Primary eosinophilic disorders: a concise review.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

4.  Fusion of platelet-derived growth factor receptor β to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature.

Authors:  Sheng-Lan Gong; Meng-Qiao Guo; Gu-Sheng Tang; Chun-Ling Zhang; Hui-Ying Qiu; Xiao-Xia Hu; Jian-Min Yang
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

Review 5.  BCR-ABL-negative chronic myeloid leukemia.

Authors:  Sonja Burgstaller; Andreas Reiter; Nicholas C P Cross
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

6.  TRIP11-PDGFRB fusion in a patient with a therapy-related myeloid neoplasm with t(5;14)(q33;q32) after treatment for acute promyelocytic leukemia.

Authors:  Hoon-Gu Kim; Ja-Hyun Jang; Eun-Ha Koh
Journal:  Mol Cytogenet       Date:  2014-12-23       Impact factor: 2.009

7.  Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11).

Authors:  Guangying Sheng; Zhao Zeng; Jinlan Pan; Linbing Kou; Qinrong Wang; Hong Yao; Lijun Wen; Liang Ma; Depei Wu; Huiying Qiu; Suning Chen
Journal:  Mol Cytogenet       Date:  2017-02-27       Impact factor: 2.009

Review 8.  PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Authors:  Mirela Andrei; Andrei Bandarchuk; Cherif Abdelmalek; Ajay Kundra; Vladimir Gotlieb; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2017-02-17

Review 9.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.